ARWR RSI Chart
Last 7 days
-3.4%
Last 30 days
-21.5%
Last 90 days
-33.3%
Trailing 12 Months
-38.5%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 272.8M | 256.2M | 240.7M | 0 |
2022 | 263.4M | 249.9M | 243.2M | 278.3M |
2021 | 89.1M | 107.6M | 138.3M | 144.4M |
2020 | 139.0M | 123.7M | 88.0M | 79.8M |
2019 | 94.8M | 136.8M | 168.8M | 163.6M |
2018 | 22.2M | 13.6M | 16.1M | 47.3M |
2017 | 18.9M | 25.2M | 31.4M | 30.6M |
2016 | 255.0K | 170.8K | 6.4M | 12.7M |
2015 | 302.0K | 382.0K | 382.0K | 255.0K |
2014 | 175.0K | 175.0K | 175.0K | 302.0K |
2013 | 294.4K | 290.3K | 290.3K | 175.0K |
2012 | 55.2K | 103.1K | 146.9K | 281.9K |
2011 | 0 | 0 | 296.1K | 24.0K |
2010 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 01, 2024 | hamilton james c | sold | -168,180 | 28.03 | -6,000 | chief discovery/trans medicine |
Mar 20, 2024 | lu hongbo | bought | 27,500 | 27.5 | 1,000 | - |
Mar 19, 2024 | lu hongbo | bought | 28,000 | 28.00 | 1,000 | - |
Mar 18, 2024 | lu hongbo | bought | 27,490 | 27.49 | 1,000 | - |
Mar 06, 2024 | myszkowski kenneth allen | sold | -1,407,600 | 35.19 | -40,000 | chief financial officer |
Jan 31, 2024 | anzalone christopher richard | acquired | 836,035 | 14.54 | 57,499 | chief executive officer |
Jan 31, 2024 | anzalone christopher richard | sold | -1,860,020 | 32.3487 | -57,499 | chief executive officer |
Jan 12, 2024 | hamilton james c | sold | -292,904 | 36.8896 | -7,940 | chief discovery/trans medicine |
Jan 11, 2024 | waddill william d. | sold | -149,759 | 38.0678 | -3,934 | - |
Jan 11, 2024 | given douglas b | sold | -110,788 | 38.0585 | -2,911 | - |
Which funds bought or sold ARWR recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 25, 2024 | Zurcher Kantonalbank (Zurich Cantonalbank) | added | 4.9 | -13,566 | 681,023 | -% |
Apr 25, 2024 | Friedenthal Financial | unchanged | - | -3,340 | 47,762 | 0.03% |
Apr 25, 2024 | Allworth Financial LP | added | 303 | 4,414 | 6,006 | -% |
Apr 25, 2024 | SIMPLEX TRADING, LLC | added | 9.75 | 15,000 | 600,000 | -% |
Apr 25, 2024 | WCM INVESTMENT MANAGEMENT, LLC | added | 30.5 | 1,092,860 | 6,451,670 | 0.01% |
Apr 25, 2024 | NEW YORK STATE TEACHERS RETIREMENT SYSTEM | added | 2.14 | -189,000 | 3,966,000 | 0.01% |
Apr 25, 2024 | Bank of New York Mellon Corp | added | 10.13 | 860,587 | 30,172,500 | 0.01% |
Apr 25, 2024 | Lindbrook Capital, LLC | reduced | -57.68 | -6,381 | 4,176 | -% |
Apr 24, 2024 | Western Financial Corp/CA | unchanged | - | -1,640,480 | 23,458,800 | 14.38% |
Apr 24, 2024 | DekaBank Deutsche Girozentrale | unchanged | - | -89,000 | 1,079,000 | -% |
Unveiling Arrowhead Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Arrowhead Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 41.2B | 6.8B | -8.75 | 6.02 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.0B | 1.8B | -41 | 9.87 | ||||
BMRN | 15.3B | 2.4B | 91.05 | 6.31 | ||||
INCY | 11.6B | 3.7B | 19.41 | 3.14 | ||||
MID-CAP | ||||||||
APLS | 5.8B | 396.6M | -10.93 | 14.57 | ||||
BBIO | 4.4B | - | -6.7 | 60.35 | ||||
AXSM | 3.4B | 270.6M | -14.22 | 12.57 | ||||
ACAD | 2.8B | 726.4M | -44.9 | 3.79 | ||||
ARWR | 2.7B | 240.7M | -9.23 | 12.18 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.58 | 4.41 | ||||
NVAX | 569.6M | 983.7M | -1.05 | 0.58 | ||||
CRBP | 361.2M | 881.7K | -8.1 | 466.16 | ||||
INO | 247.0M | 4.9M | -1.83 | 50.76 | ||||
IBIO | 6.1M | 2.1M | -0.22 | 2.14 |
Arrowhead Pharmaceuticals Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | -100.0% | - | 16,097,000 | 15,825,000 | 146,267,000 | 62,546,000 | 31,575,000 | 32,412,000 | 151,805,000 | 27,439,000 | 38,282,500 | 45,891,000 | 32,811,000 | 21,303,000 | 7,632,856 | 27,376,000 | 23,529,000 | 29,455,000 | 43,292,770 | 42,696,636 | 48,148,275 | 34,657,896 |
Operating Expenses | 12.6% | 140,096,000 | 124,427,000 | 118,528,000 | 98,102,000 | 104,680,000 | 115,405,000 | 105,321,000 | 110,252,000 | 90,760,000 | 103,165,000 | 77,759,000 | 61,043,000 | 45,357,000 | 57,752,000 | 43,322,000 | 45,769,000 | 34,308,000 | 33,654,778 | 24,100,887 | 26,137,583 | 23,711,752 |
S&GA Expenses | -3.9% | 23,605,000 | 24,572,000 | 23,771,000 | 23,221,000 | 20,985,000 | 32,028,000 | 33,141,000 | 34,267,000 | 24,995,000 | 37,399,500 | 18,434,000 | 16,346,000 | 8,802,000 | 14,267,000 | 10,749,000 | 16,326,000 | 10,934,000 | 10,268,159 | 4,809,177 | 5,338,955 | 6,139,709 |
EBITDA Margin | -52.8% | -1.12 | -0.73 | -0.62 | -0.49 | -0.51 | -0.67 | -0.57 | -0.39 | -1.20 | -0.96 | -1.10 | -1.15 | - | - | - | - | - | - | - | - | - |
Interest Expenses | 2.0% | 5,367,000 | 5,262,000 | 5,158,000 | 5,057,000 | 2,849,000 | - | - | - | - | - | - | - | - | - | - | - | - | -437 | - | - | 27,437 |
Income Taxes | -263.6% | -3,313,000 | 2,025,000 | 742,000 | - | 17,000 | 3,785,000 | - | - | - | 2,000 | - | - | - | - | - | - | - | 172,800 | - | - | - |
Earnings Before Taxes | -27.2% | -138,689,000 | -108,990,000 | -103,383,000 | 47,676,000 | -41,794,000 | -82,157,000 | -72,046,000 | 44,366,000 | -62,872,000 | -63,372,000 | -29,924,000 | -26,818,000 | -20,732,000 | -48,431,000 | -13,611,000 | -19,836,000 | -2,673,000 | 11,879,057 | 20,335,708 | 23,896,982 | 12,037,253 |
EBT Margin | -46.9% | -1.26 | -0.86 | -0.70 | -0.54 | -0.54 | -0.71 | -0.62 | -0.42 | -1.27 | -1.02 | -1.17 | -1.23 | - | - | - | - | - | - | - | - | - |
Net Income | -21.1% | -132,864,000 | -109,679,000 | -102,946,000 | 48,675,000 | -41,325,000 | -85,511,000 | -72,046,000 | 44,366,000 | -62,872,000 | -63,374,000 | -29,924,000 | -26,818,000 | -20,732,000 | -48,432,715 | -13,611,000 | -19,836,000 | -2,673,000 | 11,704,906 | 20,335,708 | 23,896,982 | 12,037,253 |
Net Income Margin | -44.6% | -1.23 | -0.85 | -0.71 | -0.55 | -0.56 | -0.72 | -0.62 | -0.42 | -1.27 | -1.02 | -1.17 | -1.23 | - | - | - | - | - | - | - | - | - |
Free Cashflow | -109.2% | -186,496,000 | -89,164,000 | -68,051,000 | -58,985,000 | -114,427,000 | -101,448,000 | -78,351,000 | 57,977,000 | -67,086,000 | -32,228,000 | -33,541,000 | 256,707,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -18.2% | 626 | 766 | 796 | 891 | 891 | 692 | 752 | 704 | 639 | 710 | 735 | 757 | 499 | 523 | 556 | 561 | 588 | 350 | 337 | 334 | 341 |
Current Assets | -43.3% | 238 | 420 | 470 | 575 | 575 | 405 | 432 | 418 | 338 | 385 | 526 | 587 | 324 | 322 | 315 | 314 | 508 | 265 | 245 | 235 | 249 |
Cash Equivalents | -47.5% | 58.00 | 111 | 105 | 135 | 202 | 108 | 139 | 86.00 | 92.00 | 184 | 326 | 372 | 140 | 144 | 219 | 257 | 461 | 222 | 188 | 162 | 190 |
Net PPE | 14.9% | 333 | 290 | 231 | 185 | 147 | 110 | 72.00 | 55.00 | 52.00 | 49.00 | 48.00 | 39.00 | 34.00 | 31.00 | 30.00 | 29.00 | 26.00 | 23.00 | 17.00 | 13.00 | 14.00 |
Current Liabilities | -39.6% | 64.00 | 105 | 70.00 | 87.00 | 122 | 139 | 128 | 139 | 137 | 147 | 195 | 167 | 25.00 | 41.00 | 43.00 | 53.00 | 74.00 | 97.00 | 87.00 | 102 | 135 |
Shareholder's Equity | -40.9% | 160 | 271 | 365 | 465 | 396 | 418 | 474 | 452 | 373 | 409 | 437 | 446 | 454 | 462 | 493 | 494 | 500 | 244 | 226 | 201 | 172 |
Retained Earnings | -12.9% | -1,158 | -1,026 | -916 | -813 | -862 | -820 | -735 | -663 | -707 | -644 | -581 | -551 | -524 | -503 | -455 | -441 | -421 | -419 | -431 | -451 | -475 |
Additional Paid-In Capital | 1.5% | 1,320 | 1,300 | 1,281 | 1,260 | 1,239 | 1,219 | 1,189 | 1,115 | 1,080 | 1,053 | 1,018 | 997 | 979 | 965 | 949 | 936 | 922 | 664 | 657 | 652 | 647 |
Shares Outstanding | 0.2% | 108 | 107 | 107 | 107 | 106 | 106 | 105 | 105 | 105 | 104 | 104 | 103 | - | - | - | - | - | - | - | - | - |
Minority Interest | -15.9% | 13.00 | 16.00 | 17.00 | 18.00 | 19.00 | 20.00 | 20.00 | - | - | - | - | - | - | - | -0.56 | -0.56 | -0.56 | -0.56 | -0.56 | -0.56 | -0.56 |
Float | - | - | - | - | 2,300 | - | - | - | 4,100 | - | - | - | 5,900 | - | - | - | 2,900 | - | - | - | 1,700 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -366.6% | -117 | -25.26 | -21.45 | -31.67 | -75.52 | -68.74 | -68.81 | 63.00 | -61.31 | -24.03 | -29.61 | 264 | -38.92 | -11.26 | -33.43 | -27.58 | -23.53 | 14.00 | 11.00 | -19.59 | 168 |
Share Based Compensation | 8.3% | 20.00 | 18.00 | 20.00 | 21.00 | 19.00 | 29.00 | 33.00 | 34.00 | 25.00 | 35.00 | 19.00 | 15.00 | 8.00 | 16.00 | 10.00 | 13.00 | 4.00 | 5.00 | 2.00 | 3.00 | 3.00 |
Cashflow From Investing | 112.5% | 65.00 | 31.00 | -9.90 | -36.06 | -80.69 | 36.00 | 61.00 | -69.75 | -33.38 | -118 | -19.54 | -34.05 | 30.00 | -65.89 | -6.03 | -178 | 9.00 | 17.00 | 14.00 | -11.22 | -67.76 |
Cashflow From Financing | 75.7% | 0.00 | 0.00 | 2.00 | 1.00 | 251 | 1.00 | 61.00 | 2.00 | 2.00 | 1.00 | 3.00 | 3.00 | 5.00 | 1.00 | 2.00 | 1.00 | 253 | 2.00 | 3.00 | 3.00 | 59.00 |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Income Statement [Abstract] | ||
Revenue | $ 3,551 | $ 62,546 |
Operating expenses: | ||
Research and development | 116,491 | 83,695 |
General and administrative | 23,605 | 20,985 |
Total operating expenses | 140,096 | 104,680 |
Operating loss | (136,545) | (42,134) |
Other income (expense): | ||
Interest income | 2,802 | 2,682 |
Interest expense | (5,367) | (2,849) |
Other, net | 421 | 507 |
Total other (expense) income | (2,144) | 340 |
Loss before income tax (benefit) expense and noncontrolling interest | (138,689) | (41,794) |
Income tax (benefit) expense | (3,313) | 17 |
Net loss including noncontrolling interest | (135,376) | (41,811) |
Net loss attributable to noncontrolling interest, net of tax | (2,512) | (486) |
Net loss attributable to Arrowhead Pharmaceuticals, Inc. | $ (132,864) | $ (41,325) |
Net loss per share attributable to Arrowhead Pharmaceuticals, Inc.: | ||
Basic (in dollars per share) | $ (1.24) | $ (0.39) |
Diluted (in dollars per share) | $ (1.24) | $ (0.39) |
Weighted-average shares used in calculating | ||
Basic (in shares) | 107,415 | 106,039 |
Diluted (in shares) | 107,415 | 106,039 |
Other comprehensive loss, net of tax: | ||
Change in unrealized losses on available-for-sale securities | $ 1,909 | $ 0 |
Foreign currency translation adjustments | 58 | (122) |
Comprehensive loss | $ (133,409) | $ (41,933) |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Sep. 30, 2023 |
---|---|---|
Current assets: | ||
Cash, cash equivalents and restricted cash | $ 58,215 | $ 110,891 |
Available-for-sale securities, at fair value | 162,064 | 292,735 |
Prepaid expenses | 10,516 | 8,813 |
Other current assets | 7,104 | 7,082 |
Total current assets | 237,899 | 419,521 |
Property, plant and equipment, net | 333,411 | 290,262 |
Intangible assets, net | 9,837 | 10,262 |
Right-of-use assets | 44,907 | 45,297 |
Other assets | 232 | 210 |
Total Assets | 626,286 | 765,552 |
Current liabilities: | ||
Accounts payable | 4,460 | 35,866 |
Accrued expenses | 46,604 | 39,763 |
Accrued payroll and benefits | 8,777 | 17,963 |
Lease liabilities | 3,421 | 10,563 |
Deferred revenue | 0 | 866 |
Other liabilities | 461 | 435 |
Total current liabilities | 63,723 | 105,456 |
Long-term liabilities: | ||
Lease liabilities, net of current portion | 115,157 | 104,608 |
Liability related to the sale of future royalties | 273,692 | 268,326 |
Total long-term liabilities | 388,849 | 372,934 |
Commitments and contingencies (Note 7) | ||
Noncontrolling interest and stockholders’ equity: | ||
Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 107,500 and 107,312 shares | 200 | 200 |
Additional paid-in capital | 1,320,356 | 1,300,395 |
Accumulated other comprehensive loss | (1,255) | (3,222) |
Accumulated deficit | (1,158,894) | (1,026,030) |
Total Arrowhead Pharmaceuticals, Inc. stockholders’ equity | 160,407 | 271,343 |
Noncontrolling interest | 13,307 | 15,819 |
Total noncontrolling interest and stockholders’ equity | 173,714 | 287,162 |
Total Liabilities, Noncontrolling Interest and Stockholders’ Equity | $ 626,286 | $ 765,552 |